AcuityMD Raises $80M to Add AI Agents for Sales Teams
AcuityMD closed an $80 million funding round Tuesday to build AI agents designed for sales representatives, leadership, and marketing teams at medical device companies. The company, which serves 16 of the top 20 medtech firms, now values at $955 million.
The platform integrates FDA records and other third-party data with a company's internal information to inform commercial decisions. AcuityMD's new AI tool, called AcuityAI, now available in open beta, helps teams extract value from that data faster than manual methods.
What the AI Does for Sales Reps
AcuityAI cuts the time needed to plan a day of customer visits. A sales rep can ask the system to prioritize high-value targets and receive an itinerary with driving routes based on existing appointments and healthcare provider schedules.
The tool also prepares reps for specific meetings by surfacing relevant context about prospects and customers.
At Kuros Biosciences, a sales leader used AcuityAI to build a business plan for a new national contract. "He quickly had a full business plan: where to go, which surgeons to prioritize and more context than he could get spending hours on Google," according to Mark Edwards, senior director of sales operations at the bone graft company.
What's Next
AcuityMD plans to expand the AI agents beyond sales to cover additional commercial roles. The company also intends to deepen its data aggregation capabilities and move beyond commercialization into other parts of the product life cycle.
Since its 2019 founding, AcuityMD has raised $160 million total. The company competes with providers like Alpha Sophia, which helps medtech sales teams identify potential customers and align offerings with hospital administrator priorities.
Learn more about AI for Sales or explore an AI Learning Path for Sales Representatives.
Your membership also unlocks:
